These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 7652899

  • 1. Sandimmun neoral improves the bioavailability of cyclosporin A and decreases inter-individual variations in patients affected with cystic fibrosis.
    Girault D, Haloun A, Viard L, Bellon G, Gottrand F, Guillemain R, Lenoir G, Ladurie FL, Plouvier E, Storni V.
    Transplant Proc; 1995 Aug; 27(4):2488-90. PubMed ID: 7652899
    [No Abstract] [Full Text] [Related]

  • 2. Safety and tolerability of Neoral in transplant recipients.
    Feutren G, Wong R, Jin J, Niese D, Mellein B.
    Transplant Proc; 1996 Aug; 28(4):2177-82. PubMed ID: 8769193
    [No Abstract] [Full Text] [Related]

  • 3. Neoral conversion study: shift from Sandimmune classic formulation to Neoral in heart and lung transplant patients.
    Svendsen UG, Larsen KR, Allermand H, Thayssen P, Jensen SB, Pettersson G.
    Transplant Proc; 1996 Aug; 28(4):2281. PubMed ID: 8769225
    [No Abstract] [Full Text] [Related]

  • 4. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
    Buchholz B, Korn A.
    Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
    [No Abstract] [Full Text] [Related]

  • 5. An investigation of the pharmacokinetics, toxicity, and clinical efficacy of Neoral cyclosporin in cystic fibrosis patients.
    Mikhail G, Eadon H, Leaver N, Rogers P, Stephens D, Banner N, Khaghani A, Yacoub M.
    Transplant Proc; 1997 Aug; 29(1-2):599-601. PubMed ID: 9123148
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic profile and variability of cyclosporine versus neoral in patients with cystic fibrosis after lung transplantation.
    Kesten S, Scavuzzo M, Chaparro C, Szalai JP.
    Pharmacotherapy; 1998 Aug; 18(4):847-50. PubMed ID: 9692659
    [Abstract] [Full Text] [Related]

  • 7. Comparison of pharmacokinetics between CsA capsules and Sandimmun Neoral in pediatric patients.
    Lin CY, Lee SF.
    Transplant Proc; 1994 Oct; 26(5):2973-4. PubMed ID: 7940938
    [No Abstract] [Full Text] [Related]

  • 8. The Swedish nationwide experience of converting transplant patients treated with Sandimmun to the new galenic formulation Sandimmun-neoral. The Swedish Sandimmun-Neoral Conversion Group.
    Wilczek HE, Berglin E, Blohmé I, Bäckman L, Fehrman I, Källen R, Nyberg G, Säwe J, Wahlberg J.
    Transplant Proc; 1997 Oct; 29(1-2):280-3. PubMed ID: 9122995
    [No Abstract] [Full Text] [Related]

  • 9. Clinical impact of Neoral in thoracic organ transplantation.
    Aziz T, el-Gamel A, Keevil B, Krysiak P, Campbell C, Rahman A, Deiraniya A, Yonan N.
    Transplant Proc; 1998 Aug; 30(5):1900-3. PubMed ID: 9723326
    [No Abstract] [Full Text] [Related]

  • 10. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
    Løkkegaard H, Asmundsson P, Clausen P, Dieperink H, Hansen JM, Heaf J, Jensen SB, Kornerup HJ, Madsen S, Pedersen EB, Poulsen JV, Rasmussen K.
    Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Conversion from cyclosporine to Neoral in pediatric recipients for kidney, liver, and heart transplantation.
    Holmberg C, Laine J, Jalanko H, Leijala M, Hoppu K.
    Transplant Proc; 1996 Aug; 28(4):2262-3. PubMed ID: 8769219
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparison of Neoral and Sandimmune preparations in renal transplant patients--improved pharmacokinetics with neoral.
    Warrens AN, Salama A, Waters JB, Lechler RI.
    Transplant Proc; 1996 Aug; 28(4):2169-70. PubMed ID: 8769190
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of neoral and sandimmun cyclosporines for de novo lung transplantation in cystic fibrosis patients.
    Mikhail G, Eadon H, Leaver N, Khaghani A, Yacoub M, Banner N.
    Transplant Proc; 1998 Jun; 30(4):1510-1. PubMed ID: 9636614
    [No Abstract] [Full Text] [Related]

  • 17. Transfer of patients with kidney grafts to Sandimmun Neoral normalizes the calcium level in erythrocyts.
    Babarykin D, Amerika D, Adamsone I, Valinietse M, Rosental R.
    Transplant Proc; 1996 Dec; 28(6):3137. PubMed ID: 8962215
    [No Abstract] [Full Text] [Related]

  • 18. [Variability of the bioavailability of cyclosporine: benefit of the Neoral formulation].
    Humbert H.
    Therapie; 1997 Dec; 52(4):353-7. PubMed ID: 9437891
    [Abstract] [Full Text] [Related]

  • 19. A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. The International Sandimmun Neoral Study Group.
    Niese D.
    Transplant Proc; 1995 Apr; 27(2):1849-56. PubMed ID: 7725531
    [No Abstract] [Full Text] [Related]

  • 20. Clinical use and bioavailability of tacrolimus in heart-lung and double lung transplant recipients with cystic fibrosis.
    Walker S, Habib S, Rose M, Yacoub M, Banner N.
    Transplant Proc; 1998 Jun; 30(4):1519-20. PubMed ID: 9636618
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.